161 related articles for article (PubMed ID: 19366275)
1. Effect of ivabradine, a novel antianginal agent, on driving performance: A randomized, double-blind, placebo-controlled trial in healthy volunteers.
Macher JP; Lévy S
Clin Drug Investig; 2009; 29(5):339-48. PubMed ID: 19366275
[TBL] [Abstract][Full Text] [Related]
2. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
Ruzyllo W; Tendera M; Ford I; Fox KM
Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
[TBL] [Abstract][Full Text] [Related]
3. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
Borer JS; Fox K; Jaillon P; Lerebours G;
Circulation; 2003 Feb; 107(6):817-23. PubMed ID: 12591750
[TBL] [Abstract][Full Text] [Related]
4. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers.
Choi HY; Noh YH; Cho SH; Ghim JL; Choe S; Kim UJ; Ah Jung J; Bae KS; Lim HS
Clin Ther; 2013 Jun; 35(6):819-35. PubMed ID: 23755867
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
Tardif JC; Ponikowski P; Kahan T;
Eur Heart J; 2009 Mar; 30(5):540-8. PubMed ID: 19136486
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study.
Jiang J; Tian L; Huang Y; Li Y; Xu L
Clin Ther; 2013 Dec; 35(12):1933-45. PubMed ID: 24332196
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
10. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
DiFrancesco D; Camm JA
Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.
Perings S; Stöckl G; Kelm M;
Adv Ther; 2016 Sep; 33(9):1550-64. PubMed ID: 27432382
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
Cappato R; Castelvecchio S; Ricci C; Bianco E; Vitali-Serdoz L; Gnecchi-Ruscone T; Pittalis M; De Ambroggi L; Baruscotti M; Gaeta M; Furlanello F; Di Francesco D; Lupo PP
J Am Coll Cardiol; 2012 Oct; 60(15):1323-9. PubMed ID: 22981555
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of I(f) current inhibition by ivabradine.
Tardif JC
Drugs; 2007; 67 Suppl 2():35-41. PubMed ID: 17999562
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
15. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
López-Bescós L; Filipova S; Martos R
Cardiology; 2007; 108(4):387-96. PubMed ID: 17890862
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
Tardif JC; Ford I; Tendera M; Bourassa MG; Fox K;
Eur Heart J; 2005 Dec; 26(23):2529-36. PubMed ID: 16214830
[TBL] [Abstract][Full Text] [Related]
17. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
Tardif JC; Ponikowski P; Kahan T;
Int J Cardiol; 2013 Sep; 168(2):789-94. PubMed ID: 23138014
[TBL] [Abstract][Full Text] [Related]
18. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
19. Absence of respiratory effects with ivabradine in patients with asthma.
Babu KS; Gadzik F; Holgate ST
Br J Clin Pharmacol; 2008 Jul; 66(1):96-101. PubMed ID: 18341671
[TBL] [Abstract][Full Text] [Related]
20. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
